SalioGen is a therapeutics company that aims to provide medical solutions through the use of gene coding. With a mission to create curative therapies for Stargardt disease and cystic fibrosis, the company uses DNA integration and broad application and reach. SalioGen was founded by Joseph Higgins in 2020 and is headquartered in Burlington, MA.
Funding Date | Share Class | Amount Raised | Price per Share | Post-Money Valuation | Key Investors | |
---|---|---|---|---|---|---|
01/05/2022 | Series B | $132.25MM | $xx.xx | $549.61MM | GordonMD Global Investments, EPIQ Capital Group, Fidelity, T. Rowe Price, D1 Capital Partners, SymBiosis, Cystic Fibrosis Foundation, RD Fund | |
Price per Share
$xx.xx
Shares Outstanding
1,249,239
Liquidation Pref Order
1
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
GordonMD Global Investments, EPIQ Capital Group, Fidelity, T. Rowe Price, D1 Capital Partners, SymBiosis, Cystic Fibrosis Foundation, RD Fund
|
||||||
03/01/2021 | Series A | $23.97MM | $xx.xx | $59.93MM | PBM Capital | |
Price per Share
$xx.xx
Shares Outstanding
1,377,646
Liquidation Pref Order
2
Liquidation Pref As Multiplier
1.0x
Conversion Ratio
1.0x
Dividend Rate
Cumulative
Non-cumulative
Participating
Non-participating
Participation Cap
N/A
Key Investors
PBM Capital
|